Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Introduction: Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Clinical Trials

Study to Evaluate The Safety and Efficacy of Balovaptan in Participants With Acute Ischemic Stroke at a High Risk of Developing Malignant Brain Edema

Phase 2

Withdrawn

Conditions: Acute Ischemic Stroke

Interventions: Drug: Placebo
Drug: Balovaptan

First Posted Date: 2022-06-01

Last Posted Date: 2023-08-07

Lead Sponsor: Hoffmann-La Roche

Registration Number: NCT05399550

Locations: 🇺🇸
CPMC Comprehensive Stroke Care Center, San Francisco, California, United States

A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma

Phase 1

Active, not recruiting

Conditions: Diffuse Large B-Cell Lymphoma (DLBCL)

Interventions: Drug: Glofitamab
Drug: Obinutuzumab
Drug: Tocilizumab
Drug: Rituximab
Drug: Ifosfamide
Drug: Carboplatin
Drug: Etoposide

First Posted Date: 2022-05-06

Last Posted Date: 2025-03-18

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 43

Registration Number: NCT05364424

Locations: 🇺🇸
Tulane Medical Center, New Orleans, Louisiana, United States
🇺🇸
Chao Family Comprehensive Cancer Center UCI, Orange, California, United States
🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States

and more 6 locations

An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma

Phase 1

Terminated

Conditions: Non-Hodgkin Lymphoma, Follicular Lymphoma

Interventions: Drug: Mosunetuzumab SC
Drug: Tiragolumab
Other: Tocilizumab
Drug: Atezolizumab

First Posted Date: 2022-04-07

Last Posted Date: 2024-10-04

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 8

Registration Number: NCT05315713

Locations: 🇧🇪
Institut Jules Bordet, Bruxelles, Belgium
🇧🇪
CHU UCL Namur - Mont-Godinne, Yvoir, Belgium
🇩🇪
Universitaet Duisburg-Essen, Essen, Germany

and more 14 locations

A Study to Evaluate the Safety and Efficacy of Basmisanil Treatment in Children Aged 2-14 Years With Dup15q Syndrome

Phase 2

Terminated

Conditions: Dup15q Syndrome

Interventions: Drug: Placebo
Drug: Basmisanil

First Posted Date: 2022-04-01

Last Posted Date: 2024-07-03

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 7

Registration Number: NCT05307679

Locations: 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
Rady Children's Hospital - San Diego, San Diego, California, United States
🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

and more 8 locations

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

Phase 3

Recruiting

Conditions: Locally Advanced or Metastatic Breast Cancer

Interventions: Drug: Phesgo
Drug: Docetaxel
Drug: LHRH Agonist
Drug: Giredestrant
Drug: Paclitaxel
Drug: Optional Endocrine Therapy of Investigator's Choice

First Posted Date: 2022-03-25

Last Posted Date: 2025-05-28

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 922

Registration Number: NCT05296798

Locations: 🇰🇷
Gangnam Severance Hospital, Seoul, Korea, Republic of
🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷
Seoul St Mary's Hospital, Seoul, Korea, Republic of

and more 234 locations

A Study in Healthy Male Subjects to Investigate the Comparability of Pharmacokinetics of the Fixed-Dose Combination of Pertuzumab and Trastuzumab Administered Subcutaneously Using a Handheld Syringe or Using the On-Body Delivery System

Phase 1

Completed

Conditions: Healthy Male Subjects

Interventions: Drug: Fixed-Dose Combination of Pertuzumab and Trastuzumab SC (PH FDC SC)
Device: Handheld Syringe with Hypodermic Needle
Device: On-Body Delivery System

First Posted Date: 2022-03-11

Last Posted Date: 2023-10-23

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 151

Registration Number: NCT05275010

Locations: 🇦🇺
CMAX Pty Ltd, Adelaide, South Australia, Australia
🇦🇺
Q-Pharm Pty Ltd; Nucleus Network Brisbane Clinic, Herston, Queensland, Australia
🇳🇿
New Zealand Clinical Research - Christchurch, Christchurch, New Zealand

and more 2 locations

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

Phase 3

Recruiting

Conditions: Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)

Interventions: Other: Placebo
Drug: Satralizumab

First Posted Date: 2022-03-09

Last Posted Date: 2025-03-17

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 152

Registration Number: NCT05271409

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Mayo Clinic- Scottsdale, Scottsdale, Arizona, United States
🇺🇸
University of California Irvine - Manchester Pavilion, Orange, California, United States

and more 72 locations

A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention

Phase 4

Terminated

Conditions: Neuromyelitis Optica Spectrum Disorder
NMOSD

Interventions: Drug: Satralizumab 120 mg

First Posted Date: 2022-03-08

Last Posted Date: 2025-01-22

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 4

Registration Number: NCT05269667

Locations: 🇹🇷
Ondokuz Mayis University School of Medicine, Samsun, Turkey
🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States
🇰🇷
National Cancer Center, Goyang-si, Korea, Republic of

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

Phase 3

Active, not recruiting

Conditions: Multiple Sclerosis

Interventions: Drug: Ocrelizumab

First Posted Date: 2022-03-07

Last Posted Date: 2025-03-17

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1300

Registration Number: NCT05269004

Locations: 🇨🇿
Krajska zdravotni a.s. - Nemocnice Teplice o.z., Teplice, Czechia
🇪🇪
West Tallinn Central Hospital, Tallinn, Estonia
🇪🇪
Tartu University Hospital, Tartu, Estonia

and more 231 locations

A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD)

Phase 3

Terminated

Conditions: Alzheimers Disease

Interventions: Drug: Placebo
Drug: Gantenerumab

First Posted Date: 2022-02-25

Last Posted Date: 2024-07-09

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 25

Registration Number: NCT05256134

Locations: 🇺🇸
Visionary Investigators Network - Neurology Aventura, Aventura, Florida, United States
🇺🇸
Neuropsychiatric Research; Center of Southwest Florida, Fort Myers, Florida, United States
🇺🇸
Premiere Research Institute, West Palm Beach, Florida, United States

and more 60 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy